Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company

AstraZeneca China Announces Leadership Changes and New Biopharmaceutical Unit

Fineline Cube Jan 16, 2024

AstraZeneca (AZ, NASDAQ: AZN)’s China unit is set to undergo significant organizational changes, including the...

Company Drug

SciClone’s Partner Menarini Files for Elacestrant Approval in Macau for Advanced Breast Cancer

Fineline Cube Jan 16, 2024

SciClone Pharmaceuticals Inc. (HKG: 6600) has announced that its Italian partner, Menarini Group, has submitted...

Policy / Regulatory

China’s State Council Unveils 26 Initiatives to Enhance Grey-hair Economy

Fineline Cube Jan 16, 2024

The State Council has unveiled the “Opinions on Developing the Grey-hair Economy to Boost Wellbeing...

Company Deals

China Grand Pharma to Acquire 63% Stake in Duoputai for RMB 442 Million

Fineline Cube Jan 16, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to...

Company Drug

Bayer’s Asklepios BioPharmaceutical Launches Phase II Trial for AAV Therapy in Heart Failure

Fineline Cube Jan 16, 2024

Bayer’s (ETR: BAYN) gene therapy subsidiary, Asklepios BioPharmaceutical, has initiated patient recruitment for a Phase...

Company Drug

CanSino Biologics Enrolls First Patient in Phase I Trial of Innovative Polio Vaccine

Fineline Cube Jan 16, 2024

CanSino Biologics (SHA: 688185, HKG: 6185), a China-based biotechnology firm, has announced the enrollment of...

Company Deals

Novartis Acquires Calypso Biotech for USD 250 Million to Bolster IL-15 Pipeline

Fineline Cube Jan 16, 2024

Novartis (NYSE: NVS) has finalized an agreement to acquire Netherlands-based Calypso Biotech, a 2013 spinout...

Company Deals

Cytokinetics Attracts Big Pharma Interest Amid Aficamten’s Phase III Success

Fineline Cube Jan 16, 2024

Cytokinetics (NASDAQ: CYTK), a specialist in cardiovascular diseases, is reportedly attracting interest from multiple Big...

Company Drug

RemeGen Secures Fast-Track Designation for RC88 in Platinum-Resistant Ovarian Cancer

Fineline Cube Jan 16, 2024

China-based biotech RemeGen Co., Ltd (HKG: 9995; SHA: 688331) has received fast-track designation (FTD) from...

Company Drug

CSPC Pharmaceutical Secures FDA Approval for Clinical Study of JMT106 in GPC3-Positive Tumors

Fineline Cube Jan 16, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received approval from the US FDA to...

Company Deals

BioNTech Acquires Pre-Clinical Asset and ADC Technology from Portuguese Biotech CellmAbs

Fineline Cube Jan 15, 2024

Germany’s BioNTech (NASDAQ: BNTX) has licensed a pre-clinical antibody candidate and additional antibody-drug conjugate (ADC)...

Company Deals

NVIDIA Expands Healthcare Reach with Amgen’s deCode Partnership at JP Morgan Conference

Fineline Cube Jan 15, 2024

At the recent JP Morgan Healthcare Conference, US chip giant NVIDIA (NASDAQ: NVDA) announced a...

Company Deals

Alphabet’s Isomorphic Labs Inks Pharma Partnerships with Eli Lilly and Novartis

Fineline Cube Jan 15, 2024

Isomorphic Labs, a drug discovery company under the umbrella of Google’s parent group Alphabet (NASDAQ:...

Company Drug

MSD’s Keytruda Gains FDA Approval for Advanced Cervical Cancer Treatment

Fineline Cube Jan 15, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has received regulatory approval from the US Food...

Company Deals

Boai NKY Medical Holdings Partners with HuaDao Biopharma for CAR-T Therapy Incubator

Fineline Cube Jan 15, 2024

Boai NKY Medical Holdings Ltd (SHE: 300109), a Chinese biotech company, has announced a strategic...

Policy / Regulatory

China’s NHSA Unveils Measures to Secure Volume-Based Procurement Supply

Fineline Cube Jan 15, 2024

The National Healthcare Security Administration (NHSA) has issued a notification outlining key measures to ensure...

Company Drug

BMS’s Mavacamten Used to Treat First Patient with Hypertrophic Cardiomyopathy in Hainan

Fineline Cube Jan 15, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has announced that the first patient with obstructive hypertrophic cardiomyopathy...

Company Deals

Shanghai’s EnjoSim Secures Tens of Millions in Pre-Series A Funding for Expansion

Fineline Cube Jan 15, 2024

EnjoSim, a Shanghai-based developer of microbiologic self-administration systems, has reportedly secured tens of millions of...

Company Deals

Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer

Fineline Cube Jan 15, 2024

Dr. Chris Boshoff, Pfizer (NYSE: PFE)’s recently appointed chief oncology officer, disclosed in an interview...

Company Drug

CARsgen Therapeutics Gets NMPA Approval for CAR-T Therapy CT011 in Hepatocellular Carcinoma

Fineline Cube Jan 15, 2024

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that it has received approval from...

Posts pagination

1 … 458 459 460 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.